乳腺癌保乳治疗后早期乳腺MR成像监测的诊断效能与乳腺组织变化
这项前瞻性研究纳入414例保乳治疗后的乳腺癌患者,共422次早期(中位6.0个月)监测性乳腺MR检查,评估MR、乳腺X线和超声的诊断效能。MR敏感度为81.8%,高于乳腺X线和超声的18.2%,但置信区间有重叠;接受辅助化疗或激素治疗者背景实质强化(BPE)显著降低。
要点
- 保乳治疗后早期监测中,MR敏感度81.8%(9/11),高于乳腺X线和超声的18.2%(2/11),但95%CI有重叠。
- 11例检出癌中6例仅MR可见,3例位于原瘤床、2例紧邻原瘤床,提示需重点观察手术床及周边。
- 2例MR假阴性均为导管原位癌,分别因仅表现为乳腺X线钙化无强化、以及明显BPE掩盖局灶病变。
核心结论
- 保乳治疗后早期MR监测对乳腺癌患者可能有用,敏感度优于乳腺X线和超声;接受辅助治疗者在短期随访MR上BPE趋于降低。
研究设计与样本
- 前瞻性研究,经机构审查委员会批准并获书面知情同意;2014年4月至2016年6月纳入414例保乳治疗后女性(平均年龄51.5岁,范围21-81岁),共422次早期监测乳腺MR检查(中位6.0个月,范围2-12个月);评估MR、乳腺X线和超声的癌检出率、活检阳性预测值、敏感度、特异度、准确度和AUC;95例女性另行PET/CT随访。
关键影像表现/征象
- 11例检出癌中6例仅MR可见,1例MR与乳腺X线均可见,2例MR与超声均可见,1例仅乳腺X线可见,1例仅PET/CT可见。
- 3例MR显示的癌位于原瘤床,2例MR显示的癌位于原肿瘤邻近。
- 2例MR假阴性均为导管原位癌:1例在乳腺X线上表现为钙化而MR无明确强化,另1例经PET/CT检出,MR因明显BPE致局灶病变被掩盖而阴性。
诊断标准与关键数值
- MR活检阳性预测值32.1%(9/28)。
- MR敏感度81.8%(9/11),特异度95.1%(391/411),准确度94.7%(400/422),AUC 0.88。
- MR敏感度81.8%(95%CI 48.2%-97.7%)高于乳腺X线18.2%(95%CI 2.3%-51.8%)和超声18.2%(95%CI 2.3%-51.8%),置信区间有重叠。
临床应用与阅片要点
- 早期监测MR检出癌多位于原瘤床或原肿瘤邻近,阅片时应重点评估手术床及周边区域。
- MR假阴性可因病变仅表现为乳腺X线钙化而无明确强化,或明显BPE掩盖局灶病变,需结合乳腺X线及PET/CT。
- 接受辅助化疗者BPE降低43例、升高4例,接受激素治疗者BPE降低55例、升高2例(两者P均<.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To investigate the diagnostic performance and tissue changes in early (1 year or less) breast magnetic resonance (MR) imaging surveillance in women who underwent breast conservation therapy for breast cancer. Materials and Methods This prospective study was approved by the institutional review board, and written informed consent was obtained. Between April 2014 and June 2016, 414 women (mean age, 51.5 years; range, 21-81 years) who underwent 422 early surveillance breast MR imaging examinations (median, 6.0 months; range, 2-12 months) after breast conservation therapy were studied. The cancer detection rate, positive predictive value of biopsy, sensitivity, specificity, accuracy, and area under the curve of surveillance MR imaging, mammography, and ultrasonography (US) were assessed. Follow-up was also obtained in 95 women by using positron emission tomography (PET)/computed tomography (CT). Background parenchymal enhancement (BPE) changes in the contralateral breast were assessed according to adjuvant therapy by using the McNemar test. Results Of 11 detected cancers, six were seen at MR imaging only, one was seen at MR imaging and mammography, two were seen at MR imaging and US, one was seen at mammography only, and one was seen at PET/CT only. Three MR imaging-depicted cancers were observed at the original tumor bed, and two MR imaging-depicted cancers were observed adjacent to the original tumor. Among two false-negative MR imaging diagnoses (two cases of ductal carcinoma in situ), one cancer had manifested as calcifications at mammography without differentiated enhancement at MR imaging, and the other cancer was detected at PET/CT, but MR imaging results were negative because of marked BPE, which resulted in focal lesion masking. The positive predictive value of biopsy and the sensitivity, specificity, accuracy, and area under the curve for MR imaging were 32.1% (nine of 28), 81.8% (nine of 11), 95.1% (391 of 411), 94.7% (400 of 422), and 0.88, respectively. The sensitivity of surveillance MR imaging (81.8%; 95% confidence interval [CI]: 48.2%, 97.7%) was higher than that of mammography (18.2%; 95% CI: 2.3%, 51.8%) and US (18.2%; 95% CI: 2.3%, 51.8%), with an overlap in CIs. The BPE showed a significant decrease in the group of patients who received adjuvant chemotherapy (43 BPE decreases and four BPE increases) and the group of patients who received hormone therapy (55 BPE decreases and two BPE increases) (P < .0001 for both). Conclusion Early MR imaging surveillance after breast conservation therapy can be useful in patients who have breast cancer, with superior sensitivity compared with that of mammography and US. The BPE tends to be decreased at short-term follow-up MR imaging in patients who receive adjuvant therapy. © RSNA, 2017.
引用
- Kim EJ, Kang BJ, Kim SH, et al. Diagnostic Performance of and Breast Tissue Changes at Early Breast MR Imaging Surveillance in Women after Breast Conservation Therapy. Radiology. 2017. PMID: 28419815. doi:10.1148/radiol.2017162123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。